Used in targeted cancer therapy, particularly in the treatment of solid tumors such as lung and pancreatic cancers. It binds specifically to the LYPD3 (also known as C4.4A) protein, which is overexpressed on tumor cells but has limited expression in normal tissues, making it a suitable target for antibody-based treatments. As a reference antibody, it serves as a benchmark in the development and validation of diagnostic assays and therapeutic candidates. It supports research in tumor imaging, drug conjugation strategies, and evaluation of target engagement in preclinical studies. Its high specificity enables accurate detection of LYPD3 in immunohistochemistry and flow cytometry, aiding in patient selection and biomarker analysis.